Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 May;67(5):1065–1070. doi: 10.1038/bjc.1993.195

The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.

J Fisken 1, J E Roulston 1, C Sturgeon 1, R A Badley 1, I Jönrup 1, L Aspinall 1, R C Leonard 1
PMCID: PMC1968421  PMID: 8494699

Abstract

We assayed serum HMFG2 in serial samples from 215 primary epithelial ovarian cancer patients using an 'in-house' single determinant ELISA, 45% of patients with stage I, 54% with stage II, 61% with stage III and 75% with stage IV disease had elevated serum HMFG2. Post-operative levels were significantly related with residual tumour volume (P < 0.005), and fell in the majority of responders, although the association with response to first-line chemotherapy was not significant. HMFG2 had a sensitivity of 50% specificity of 83%, accuracy of 61%, PVP of 86% and PVN of 45% for disease at second-look laparotomy. Serial levels gave a lead time to clinical relapse in 47% of patients who responded to therapy, including one patient with negative CA125 levels. HMFG, paralleled CA125 in many respects, although it was elevated in fewer patients. In a stepwise discriminant analysis, HMFG2 added to the discrimination of CA125 (r = 0.183, P < 0.005), although additional accurate information was only given in patients with advanced poorly differentiated serous cystadenocarcinoma. Given that HMFG2 is expressed in few patients who are CA125 negative it is unlikely that it will have a significant clinical impact upon patient management.

Full text

PDF
1065

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashorn P., Kallioniemi O. P., Hietanen T., Ashorn R., Krohn K. Elevated serum HMFG antigen levels in breast and ovarian cancer patients measured with a sandwich ELISA. Int J Cancer Suppl. 1988;2:28–33. doi: 10.1002/ijc.2910410710. [DOI] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  4. Burchell J., Durbin H., Taylor-Papadimitriou J. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J Immunol. 1983 Jul;131(1):508–513. [PubMed] [Google Scholar]
  5. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987 Oct 15;47(20):5476–5482. [PubMed] [Google Scholar]
  6. Burchell J., Wang D., Taylor-Papadimitriou J. Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int J Cancer. 1984 Dec 15;34(6):763–768. doi: 10.1002/ijc.2910340605. [DOI] [PubMed] [Google Scholar]
  7. Ceriani R. L., Sasaki M., Sussman H., Wara W. M., Blank E. W. Circulating human mammary epithelial antigens in breast cancer. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5420–5424. doi: 10.1073/pnas.79.17.5420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Epenetos A. A., Britton K. E., Mather S., Shepherd J., Granowska M., Taylor-Papadimitriou J., Nimmon C. C., Durbin H., Hawkins L. R., Malpas J. S. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. doi: 10.1016/s0140-6736(82)90046-0. [DOI] [PubMed] [Google Scholar]
  9. Fisken J., Leonard R. C., Badley A., Jönrup I., Aspinall L., Sturgeon C., Roulston J. E. Serological monitoring of epithelial ovarian cancer. Dis Markers. 1991 May-Aug;9(3-4):175–190. [PubMed] [Google Scholar]
  10. Gendler S. J., Lancaster C. A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E. N., Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990 Sep 5;265(25):15286–15293. [PubMed] [Google Scholar]
  11. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 1988 Sep 15;263(26):12820–12823. [PubMed] [Google Scholar]
  12. Griffiths A. B., Burchell J., Gendler S., Lewis A., Blight K., Tilly R., Taylor-Papadimitriou J. Immunological analysis of mucin molecules expressed by normal and malignant mammary epithelial cells. Int J Cancer. 1987 Sep 15;40(3):319–327. doi: 10.1002/ijc.2910400307. [DOI] [PubMed] [Google Scholar]
  13. Jacobs I., Bast R. C., Jr The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1–12. doi: 10.1093/oxfordjournals.humrep.a136832. [DOI] [PubMed] [Google Scholar]
  14. Luesley D., Lawton F., Blackledge G., Hilton C., Kelly K., Rollason T., Wade-Evans T., Jordan J., Fielding J., Latief T. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet. 1988 Sep 10;2(8611):599–603. doi: 10.1016/s0140-6736(88)90640-x. [DOI] [PubMed] [Google Scholar]
  15. Mort A. J., Lamport D. T. Anhydrous hydrogen fluoride deglycosylates glycoproteins. Anal Biochem. 1977 Oct;82(2):289–309. doi: 10.1016/0003-2697(77)90165-8. [DOI] [PubMed] [Google Scholar]
  16. Price M. R., Briggs S., Scanlon M. J., Tendler S. J., Sibley P. E., Hand C. W. The mucin antigens: what are we measuring? Dis Markers. 1991 May-Aug;9(3-4):205–212. [PubMed] [Google Scholar]
  17. Swallow D. M., Gendler S., Griffiths B., Corney G., Taylor-Papadimitriou J., Bramwell M. E. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature. 1987 Jul 2;328(6125):82–84. doi: 10.1038/328082a0. [DOI] [PubMed] [Google Scholar]
  18. Swallow D. M., Griffiths B., Bramwell M., Wiseman G., Burchell J. Detection of the urinary 'PUM' polymorphism by the tumour-binding monoclonal antibodies Ca1, Ca2, Ca3, HMFG1, and HMFG2. Dis Markers. 1986 Dec;4(4):247–254. [PubMed] [Google Scholar]
  19. Taylor-Papadimitriou J., Peterson J. A., Arklie J., Burchell J., Ceriani R. L., Bodmer W. F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer. 1981 Jul 15;28(1):17–21. doi: 10.1002/ijc.2910280104. [DOI] [PubMed] [Google Scholar]
  20. Ward B. G., Cruickshank D. J. Circulating tumor-associated antigen detected by the monoclonal antibody HMFG2 in human epithelial ovarian cancer. Int J Cancer. 1987 Jan 15;39(1):30–33. doi: 10.1002/ijc.2910390107. [DOI] [PubMed] [Google Scholar]
  21. van der Zee A. G., Duk J. M., Aalders J. G., Boontje A. H., ten Hoor K. A., de Bruijn H. W. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol. 1990 Oct;97(10):934–938. doi: 10.1111/j.1471-0528.1990.tb02450.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES